UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(MARK ONE)

     [X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
          ACT OF 1934

                  For the quarterly period ended June 30, 2005

     [ ]  TRANSITION   REPORT  UNDER  SECTION  13 OR A5(d)  OF  THE  SECURITIES
          EXCHANGE ACT OF 1934


                         Commission file number 0-23544

                         HUMAN PHEROMONE SCIENCES, INC.
                 ----------------------------------------------
                 (Name of small business issuer in its charter)


           California                                    94-3107202
--------------------------------            ------------------------------------
(State or other jurisdiction of             (I.R.S. employee Identification No.)
 incorporation or organization)


  84 West Santa Clara Street, San Jose, California               95113
----------------------------------------------------   ------------------------
     (Address of principal executive offices)                  (Zip code)


                    Issuer's telephone number: (408) 938-3030


                                 Not applicable
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)


         Check whether the issuer (1) filed all reports  required to be filed by
Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing requirements for the past 90 days.
                                                                Yes [ X ] No [ ]

         State the number of shares  outstanding of each of the issuer's classes
of common equity, as of the latest practicable date:  4,151,954 shares of Common
Stock as of July 29, 2005. 1

<PAGE>


<TABLE>
<CAPTION>
                         HUMAN PHEROMONE SCIENCES, INC.

                                      INDEX
                                                                                                                  Page
PART I
FINANCIAL INFORMATION

         Item 1. Financial Statements
<S>     <C>       <C>                                                                                                <C>

                  Balance Sheets as of June 30, 2005 (Unaudited) and December 31, 2004 ............................. 3

                  Statements of Operations (Unaudited) for the Three and Six Months Ended
                  June 30, 2005 and 2004 ........................................................................... 4

                  Statements of Cash Flows (Unaudited) for the Three and Six Months Ended
                  June 30, 2005 and 2004 ........................................................................... 5

                  Notes to Financial Statements (Unaudited) ........................................................ 6

         Item 2. Management's Discussion and Analysis

                  Management's Discussion and Analysis of Financial Conditions and Results of Operations ........... 7

         Item 3. Controls and Procedures ...........................................................................11

PART II
OTHER INFORMATION

         Item 6. Exhibits ..........................................................................................12

SIGNATURES .........................................................................................................13
</TABLE>

                                        2
<PAGE>

                                     PART I
                              FINANCIAL INFORMATION

Item 1.  Financial Statements

                         Human Pheromone Sciences, Inc.
                                 Balance Sheets
<TABLE>
<CAPTION>
                                                                              June 30,   December 31,
(in thousands except share data)                                                2005        2004
---------------------------------------------------------------------------   ---------   --------
                                                                             (unaudited)
Assets
Current assets:
<S>                                                                           <C>         <C>
  Cash and cash equivalents                                                   $    803    $  1,201
  Accounts receivable, net of allowances of $3,000 and $5,000, respectively         81         259
  Inventories, net                                                                  57          63
  Other current assets                                                              35           8
                                                                              --------    --------
Total current assets                                                               976       1,531

Property and equipment, net                                                         13          17
                                                                              --------    --------
                                                                              $    989    $  1,548
                                                                              ========    ========
Liabilities and Shareholders' Equity
Current liabilities:
 Accounts payable                                                             $     38    $     41
 Accrued professional fees                                                          55          58
 Accrued employee benefits                                                          25          35
 Accrued sales returns                                                              31          40
 Accrued income tax                                                                  2           3
 Other accrued expenses                                                             14          18
                                                                              --------    --------
    Total current liabilities                                                      165         195
                                                                              --------    --------
    Total liabilities                                                              165         195

Commitments and Contingencies

Shareholders' equity:
   Common stock, no par value, 13,333,333 shares authorized, 4,151,954
    shares issued and outstanding at each date                                  20,809      20,809
  Accumulated deficit                                                          (19,985)    (19,456)
                                                                              --------    --------
Total shareholders' equity                                                         824       1,353
                                                                              --------    --------
                                                                              $    989    $  1,548
                                                                              ========    ========

</TABLE>
See accompanying notes to financial statements.

                                        3
<PAGE>

                         Human Pheromone Sciences, Inc.
                            Statements of Operations
                                   (unaudited)
<TABLE>
<CAPTION>
                                                                     Three months ended June 30,    Six months ended June 30,
                                                                     ---------------------------    -------------------------
(in thousands except per share data)                                      2005         2004             2005         2004
                                                                        -------      -------          -------      -------
<S>                                                                         <C>          <C>              <C>          <C>
Net revenues                                                                131          149              257          408
Cost of goods sold                                                           17           33               58           73
                                                                        -------      -------          -------      -------
Gross profit                                                                114          116              199          335

Operating Expenses:
   Research and development                                                  48            7               94           16
   Selling, general and administrative                                      319          388              645          689
                                                                        -------      -------          -------      -------
Total operating expenses                                                    367          395              739          705
                                                                        -------      -------          -------      -------
Loss from operations                                                       (253)        (279)            (540)        (370)
Other income
   Interest income, net                                                       5            4               11            7
                                                                        -------      -------          -------      -------
Loss from on-going operations                                              (248)        (275)            (529)        (363)
Net gain from sale of assets                                               --              1             --              1
                                                                        -------      -------          -------      -------
Net loss                                                                $  (248)     $  (274)         $  (529)     $  (362)
                                                                        =======      =======          =======      =======
Net loss per common share - basic and fully diluted
    From on-going operations                                            $ (0.06)     $ (0.07)         $ (0.13)     $ (0.09)
    From assets sold                                                    $ (0.00)     $ (0.00)         $ (0.00)     $ (0.00)
                                                                        -------      -------          -------      -------
Net loss per common share - basic and fully diluted                     $ (0.06)     $ (0.07)         $ (0.13)     $ (0.09)
                                                                        =======      =======          =======      =======

Weighted average common shares outstanding -basic and fully diluted       4,152        4,106            4,152        4,105
                                                                        =======      =======          =======      =======
</TABLE>
See accompanying notes to financial statements.

                                       4
<PAGE>

                         Human Pheromone Sciences, Inc.
                            Statements of Cash Flows
                                   (unaudited)

<TABLE>
<CAPTION>
                                                                                    Six months ended June 30,
                                                                                    -------------------------
(in thousands)                                                                         2005          2004
--------------------------------------------------------------------------------     --------      --------
Cash flows from operating activities
<S>                                                                                  <C>          <C>
Net loss from ongoing operations                                                     $  (529)     $  (363)

 Adjustments to reconcile net loss to net cash provided by
 (used in) operating activities:
  Depreciation and amortization                                                            5            3
  Changes in operating assets and liabilities:
    Accounts receivable                                                                  178          (41)
    Inventories                                                                            6          (22)
    Other current assets                                                                 (26)         (27)
    Accounts payable and accrued liabilities                                             (31)         (12)

                                                                                     -------      -------
Net cash used in operating activities                                                   (397)        (462)
                                                                                     -------      -------

Cash flows provided by (used in) investing activities
Acquisition of property and equipment                                                     (1)         (16)
Sale of Realm assets                                                                    --              1
                                                                                     -------      -------
Net cash used in investing activities                                                     (1)         (15)

Cash flows used in financing activities                                                 --           --
                                                                                     -------      -------

Net cash used in financing activities                                                   --           --

Net decrease in cash and cash equivalents                                               (398)        (477)
Cash and cash equivalents at beginning of period                                       1,201        1,950
                                                                                     -------      -------
Cash and cash equivalents at end of period                                           $   803      $ 1,473
                                                                                     =======      =======

</TABLE>
See accompanying notes to financial statements.

                                       5
<PAGE>

                          Notes to Financial Statements
                                   (unaudited)
                                  June 30, 2005


1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Operations

     Human  Pheromone  Sciences,  Inc. (the  "Company") was  incorporated in the
State of  California  in 1989 under the name of EROX  Corporation.  The  Company
changed the name to Human Pheromone  Sciences,  Inc. in May 1998. The Company is
engaged in the research, development, manufacturing and marketing of synthesized
human pheromones and consumer products containing  synthetic human pheromones as
a component.  The Company  initiated  commercial  operations in late 1994 with a
line of fine fragrances and toiletries.  In April 2000, the Company licensed the
sale of its REALM(R)  fragrance  products and in April 2003 the Company sold the
REALM and innerREALM(R) brands and trademarks to Niche Marketing Group, Inc. The
Company's  strategic  focus is now on  expanding  the  market  for its  existing
patented pheromones to other consumer product and fragrance companies and to the
development of its internally developed brand of pheromone-based  products under
the Natural  Attraction(R)  brand,  and mood based  products  under the licensed
Demeter Natural  Attraction label. The Company will seek to add to this group of
products new,  patented  compounds that might be developed  through the research
efforts that the Company is now directly managing.

Basis of Presentation

     The  accompanying  unaudited  financial  statements  have been  prepared in
accordance with accounting principles generally accepted in the United States of
America for interim  financial  information  and with the  instructions  to Form
10-QSB and Item 310(b) of Regulation S-B.  Accordingly,  they do not include all
of the information  and footnotes  required by accounting  principles  generally
accepted in the United States of America for complete financial  statements.  In
the opinion of  management,  all  adjustments  (consisting  of normal  recurring
accruals)  considered  necessary  for a fair  presentation  have been  included.
Operating  results  for the three and six  months  ended  June 30,  2005 are not
necessarily indicative of the results that may be expected for the calendar year
ending  December  31,  2005.  For further  information,  refer to the  financial
statements and footnotes thereto included in the Company's annual report on Form
10-KSB for the year ended December 31, 2004.

Revenue Recognition

     Revenue is recorded at the time of merchandise shipment,  net of provisions
for returns. The Company records revenues from sales, initiated by sales agents,
net of the  sales  commissions  earned  following  the  interpretative  guidance
provided  by FASB  Emerging  Issue Task Force  (EITF) EITF No.  99-19  Reporting
Revenue  Gross as a Principal  versus Net as an Agent.  License  fees are earned
over the license  period  according  to the terms of the license  agreement  and
interpretative  guidance provided by Staff Accounting Bulletin (SAB) No. 101 and
No. 104. The majority of the Company's sales are to distributors  and licensees,
and these distributors and licensees have no right to return products.

Inventories

     Inventories  are stated at the lower of cost  (first in - first out method)
or market. A summary of inventories follows (in thousands):


                                                 June 30,         December 31,
                                                   2005              2004
                                                  ------            -------
    Components (raw materials)                    $   45            $   62
    Finished goods                                    30                18
    Reserve for shrinkage and obsolescence           (18)              (17)
                                                  ------            ------
                                                  $   57            $   63
                                                  ======            ======

                                       6
<PAGE>


Earnings (Loss) Per Share

     The Company  follows the  provisions  of SFAS No. 128,  Earnings Per Share.
SFAS No. 128 provides for the calculation of "Basic" and "Diluted"  earnings per
share.  Basic earnings  (loss) per share is computed using the  weighted-average
number  of common  shares  outstanding.  Diluted  earnings  (loss)  per share is
computed using the weighted-average  number of common shares and dilutive common
shares outstanding during the period. For the six months ended June 30, 2005 and
2004,   options  to  purchase   140,000  and  80,000  shares  of  common  stock,
respectively,  were excluded from the computation of diluted  earnings per share
since their effect would be antidilutive.

As of June 30,  2005 and 2004,  the  unaudited  components  of basic and diluted
earnings per share are as follows (all amounts are in thousands):

                                                              2005        2004
                                                             ------      ------
    Net income (loss) available to common shareholders       $ (529)     $ (362)
                                                             ======      ======
    Weighted-average common shares outstanding during the
    period                                                    4,152       4,105
                                                             ======      ======



Capital Stock and Stock Options

     During the three  months  ended June 30, 2005 no common  stock or preferred
stock  was  issued.  During  the  quarter,  no  stock  options  under  the  2003
Non-Employee  Directors  Stock Option Plan were granted,  no issued options were
exercised  and  9,999  stock  options  expired  under the  initial  Non-Employee
Directors Stock Option Plan.

2. SEGMENT INFORMATION

     Revenues by geographic  markets for the three and six months ended June 30,
2005 and 2004 were as follows:

                              Three months ending         Six months ending
                                    June 30,                   June 30,
                           -------------------------  -------------------------
                              2005           2004         2005           2004
                           ----------    ----------   ----------     ----------
 Markets:
  U.S Markets               $  128          $ 132       $  175        $   350
  International Markets          3             17           82             58
                           ----------    ----------   ----------     ----------
  Net Sales                 $  131          $ 149       $  257        $   408
                           ==========    ==========   ==========     ==========


Item 2. Management's Discussion and Analysis of Financial Conditions and Results
        of Operations
------  -----------------------------------------------------------------------

     This  report  contains  forward-looking  statements  within the  meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange  Act  of  1934,  as  amended.  Except  for  the  historical
information contained in this discussion and analysis of financial condition and
results  of  operations,  the  matters  discussed  herein  are  forward  looking
statements.  These forward looking statements include but are not limited to the
Company's  plans for sales  growth and  expansion  into new  channels  of trade,
expectations  of gross  margin,  expenses,  new  product  introduction,  and the
Company's   liquidity  and  capital  needs.  These  matters  involve  risks  and
uncertainties  that could cause  actual  results to differ  materially  from the
statements made. In addition to the risks and  uncertainties  described in "Risk
Factors",  below,  these risks and  uncertainties  may include  consumer trends,
business cycles,  scientific  developments,  changes in governmental  policy and
regulation,  currency  fluctuations,  economic  trends in the United  States and
inflation. These and other factors may cause actual results to differ materially
from those anticipated in forward-looking statements.  Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as
of the date hereof.

                                       7
<PAGE>

CRITICAL ACCOUNTING POLICIES

     Our  discussion  and analysis of our  financial  conditions  and results of
operations are based upon our financial statements,  which have been prepared in
accordance with accounting principles generally accepted in the United States of
America.  The  preparation of financial  statements  require  management to make
estimates  and  judgments  that  affect  the  reported  amounts  of  assets  and
liabilities,  revenues and expenses and disclosures on the date of the financial
statements. On an on-going basis, we evaluate our estimates,  including, but not
limited  to,  those  related to revenue  recognition  and license  fees.  We use
authoritative pronouncements, historical experience and other assumptions as the
basis for making judgments. Actual results could differ from those estimates. We
believe  that  the  following  critical  accounting  policies  affect  our  more
significant  judgments  and  estimates  in  the  preparation  of  our  financial
statements.

Revenue Recognition

     Revenue is recorded at the time of merchandise shipment,  net of provisions
for returns. The Company records revenues from sales, initiated by sales agents,
net of the  sales  commissions  earned  following  the  interpretative  guidance
provided  by FASB  Emerging  Issue Task Force  (EITF) EITF No.  99-19  Reporting
Revenue  Gross as a Principal  versus Net as an Agent.  License  fees are earned
over the license  period  according  to the terms of the license  agreement  and
interpretative  guidance provided by Staff Accounting Bulletin (SAB) No. 101 and
No. 104. The majority of the Company's sales are to distributors  and licensees,
and these distributors and licensees have no right to return products.

COMPANY OVERVIEW

     The  Company is engaged in the  research,  development,  manufacturing  and
marketing of consumer products  containing  synthetic human pheromones and other
mood enhancing compounds.  The Company initiated  commercial  operations in late
1994 with a line of fine fragrances and  toiletries.  Licensing of the Company's
technology is currently the core business of the Company while directly managing
the on-going development of identified compounds for potential new products. The
Company's  patented  compounds  are sold to licensed  customers  and included as
components  in their  fragranced  consumer  products.  The  Company  also offers
private label manufacturing services for third party consumer product licensees.

Results of Operations

Three  Months  ended June 30, 2005  compared to the Three  Months ended June 30,
2004

     Net revenues for the second quarter of 2005 were  $131,000,  representing a
12% decrease from the prior year's revenues of $149,000. Domestically,  revenues
were  $4,000  less than the prior  year,  attributable  to  increased  pheromone
reorders for the current  quarter  unable to offset the decreased  revenues from
the  Demeter   Natural   Attraction(R)   product  line.   The  Demeter   Natural
Attraction(R)  product line was launched in April 2004 and  generated 36% of the
domestic  revenues  during the 2004  period  which the Company did not expect to
maintain in 2005. Reorders revenues from existing customers were slightly better
than the previous  year as the timing of the customers  reorders  continue to be
placed in a non-cyclical manner.  International  revenues were $14,000 less than
the prior year due to  increased  sales in the first  three  months of the year,
$38,000 more than the prior year.

     Net revenue for the  quarters  ended June 30, 2004 and 2003 were as follows
(in thousands):

                                2005      2004
                               ------    ------
    Markets:
     U.S Markets               $  128    $  132
     International Markets          3        17
                               ------    ------
     Net Sales                 $  131    $  149
                               ======    ======


     Gross  profit for the  quarter  ended June 30,  2005 of $114,000 is 2% less
than last year's  gross  profit of $116,000.  As a  percentage  of sales,  gross
profit of 87% was more than last year's of 78%. The  increased  gross margin was
caused by a favorable sales mix of higher margin products for the current period
compared to last year's sales mix.

     Research and Development  expenses for the second quarters of 2005 and 2004
were $48,000 and $7,000, respectively. The increase of the research expenditures
was the result of the Company inaugurating  operations at the University of Utah
under the Research  Agreement  signed July 13, 2004. The Company is now directly
managing and conducting all research and development efforts from this facility.

                                       8
<PAGE>

     Selling,  general and administrative  expenses of $319,000 are $69,000 less
than last years  $388,000.  Selling,  marketing and  distribution  expenses were
$61,000  less than the prior year as the Company did not spend at the same level
as in 2004 when the Company launched its Natural Attraction(R) from Demeter line
of fragrances in the U.S.  marketplace.  General and administrative and facility
costs  decreased by $7,000,  primarily as a result of a reduction in  consulting
costs associated with the Company's  efforts to expand new investment  potential
and increase its shareholder base.

     The Company earned $5,000 and $4,000 in net interest  income in both of the
periods, respectively.

     The Company recorded no income tax provision in 2005 or 2004, due primarily
to a valuation  allowance on deferred tax assets being recorded and the expected
utilization of net operating  losses carried  forward from prior years to offset
any significant tax liability. As of June 30, 2005, the Company's gross deferred
tax asset,  which relates  primarily to net operating losses carried forward was
$6,762,000.  However,  a full  valuation  allowance  is  provided  for the gross
deferred tax asset as management could not determine  whether its realization is
more likely than not.

Six Months ended June 30, 2005 as compared to the Six Months ended June 30, 2004

     Net revenues for the six months ended June 30, 2005 were $257,000. This was
a 37%  decrease  from net  revenues  of  $408,000  for the  first  half of 2004.
Domestically,  revenues were $175,000  less than the prior years  $350,000.  The
Company's  domestic fourth quarter 2004 sales were $360,000,  a $228,000,  173%,
increase from the 2003 fourth quarter revenues.  Domestic customers seem to have
altered their historical  purchasing  patterns which resulted in increased sales
in the last quarter of 2004 and decreased revenues in the current period.  Since
the Company is not always aware of its  customer's  manufacturing  and marketing
plans  revenue   fluctuations   due  to  the  customer   schedules   will  occur
periodically.  International  revenues were $24,000  greater than the prior year
due to increased sales in the Asia and Latin America markets

     Net  revenues  for the six  months  ended  June 30,  2005 and 2004  were as
follows:

----------------------------------------- ------- -------- ------
 Markets                                    2005            2004
----------------------------------------- ------- -------- ------
  U.S Markets                             $   175          $  350
  International Markets                        82              58
                                          -------          ------
  Net Revenues                            $   257          $  408
                                          =======          ======


     Gross  profit for the first half of 2005  decreased  41% to  $199,000  from
$335,000 in 2004.  The  decrease  is the result of the reduced  sales due to the
customer ordering  patterns noted above.  Gross margin increased to 82% compared
to 77% in 2004 due to a favorable sales mix of higher margin products.

     Research and Development  expenses for the first half of 2005 and 2004 were
$94,000 and $16,000, respectively. The increase of the research expenditures was
the result of the Company  inaugurating  operations  at the  University  of Utah
under the Research  Agreement  signed July 13, 2004. The Company is now directly
managing and conducting all research and development efforts from this facility.

     Selling,  general and  administrative  expenses  for the first half of 2005
were  $645,000  and  $689,000  for the  comparable  period  of 2004,  a  $44,000
reduction.  Selling,  marketing and distribution  expenses are $68,000 less than
the prior year as the Company did not launch any new  products  lines in 2005 as
it did in 2004. General, administrative and facility expenses were $ 26,000 more
than last year  primarily  due to increased  fees  related to patent,  audit and
consulting services.

     The Company's cash balances generated $11,000 in net interest income during
the first half of 2005,  as compared to $7,000 in 2004.  The  increase is due to
increased interest rates.

                                       9
<PAGE>

LIQUIDITY AND CAPITAL RESOURCES

     At June 30, 2005, the Company had cash of $803,000 with no outstanding bank
borrowings and working capital of $811,000. At December 31, 2004, it had cash of
$1,201,000   with  no  outstanding   bank  borrowings  and  working  capital  of
$1,336,000.  For the  first  six  months  of  2005,  net cash  used in  on-going
activities  was $397,000  compared to the prior years $461,000 and is the result
of  collections  from the  higher  than  usual  accounts  receivable  balance at
December 31, 2004.

     The Company did not renew its Business Loan  Agreement  with  Mid-Peninsula
Bank of Palo  Alto,  California  (the  "Bank")  which had been  providing  for a
revolving line of credit,  secured  primarily by the Company's trade receivables
and inventory.  The agreement  which expired on May 3, 2005 was never drawn upon
by the Company.

     Assuming the Company's  activities  proceed  substantially as planned,  the
Company's current cash position and projected results of operations for the next
twelve months are not expected to require additional outside financing. However,
management  is  reviewing  additional  sources of cash  should  the  operational
requirements warrant additional funding and has hired an investment banking firm
to assist in this area.

Risk Factors

     The Company's  future results may be affected to a greater or lesser degree
by the following factors, among others:

     The Company has not had sustained  profitable  operations since 1997. Since
1997, the Company has incurred losses from  operations.  In May 2000 the Company
refocused its business model based on product  licensing  agreements.  While the
Company  anticipates  that this change in its business will result in profitable
operations,  it has not to date, and the Company's  license based business model
may not be successful in the future.

     The Company's marketing strategy may not be successful. The Company may not
be able to establish and maintain the necessary sales and distribution channels.
Consumer product and traditional  fragrance  companies may choose not to license
or private label the Company's products.

     The Company may not be able to protect its technology or trade secrets. The
Company's  patents  and  patent  applications  may  not  protect  the  Company's
technology or ensure that the Company's  technology does not infringe  another's
valid  patent.  Others  may  independently   develop  substantially   equivalent
proprietary information.  The Company may not be able to protect its technology,
proprietary information or trade secrets.

     The  Company  may not be able to  develop  new  patentable  compounds.  The
Company's  success  substantially  depends upon developing and obtaining patents
for new mood and sensory  enhancing  compounds.  The Company  requires  that its
products  be  scientifically  tested  validating  the  human  responses  to  the
compounds.  The Company may not be  successful  in  validating  that the desired
human responses are obtained.

     The  Company  may not be able to  recruit  and retain  key  personnel.  The
Company's  success  substantially  depends upon  recruiting  and  retaining  key
employees and  consultants  with  research,  product  development  and marketing
experience.  The Company may not be successful in recruiting and retaining these
key people.

     The Company relies upon other  companies to manufacture  its products.  The
Company and its distributors/licensees  rely upon other companies to manufacture
its pheromones,  supply components, and to blend, fill and package its fragrance
products. The Company and its  distributors/licensees  may not be able to obtain
or  retain   pheromone   manufacturers,   fragrance   suppliers,   or  component
manufacturers  on  acceptable  terms.  This  would  adversely  affect  operating
results.

                                       10
<PAGE>

Item 3.  Controls and Procedures

     Evaluation of Disclosure Controls and Procedures. Based on their evaluation
as of the end of the period covered by this Quarterly Report on Form 10-QSB, our
chief  executive  officer and chief  financial  officer have  concluded that our
disclosure  controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)
of the Securities Exchange Act of 1934) are effective to ensure that information
required  to be  disclosed  by us in  reports  that we file or submit  under the
Securities Exchange Act of 1934 is recorded, processed,  summarized and reported
within the time periods  specified in Securities and Exchange  Commission  rules
and forms.

     Changes in Internal Control Over Financial Reporting. There were no changes
in our internal control over financial  reporting  identified in connection with
our  evaluation  that  occurred  during  our  second  fiscal  quarter  that have
materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.

                                       11
<PAGE>


                                     PART II
                                OTHER INFORMATION

Item 6.  Exhibits
-------  --------

         a. Exhibits

          Exhibit  31.1   Certification   Pursuant   to   Section   302  of  the
                          Sarbanes-Oxley Act

          Exhibit  31.2   Certification   Pursuant   to   Section   302  of  the
                          Sarbanes-Oxley Act

          Exhibit  32     Certification  of Chief Executive  Officer  and  Chief
                          Financial Officer Pursuant to 18 U.S.C. 1350



                                       12
<PAGE>


                                   SIGNATURES


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant had duly caused this Report to be signed on behalf by the undersigned
thereunto duly authorized.


                                        HUMAN PHEROMONE SCIENCES, INC.


Date:  August 8, 2005                   /s/ William P. Horgan
                                        ---------------------
                                            William P. Horgan
                                            Chairman and Chief Executive Officer


Date:  August 8, 2005                   /s/ Gregory S. Fredrick
                                        -----------------------
                                            Gregory S. Fredrick
                                            Chief Financial Officer


                                       13